Choroidal Neovascular Membrane in Pediatric Patients: Long-Term Outcomes of Anti-VEGF Therapy
Jazyk angličtina Země Česko Médium print
Typ dokumentu časopisecké články
PubMed
40843647
DOI
10.31348/2025/33
PII: 141373
Knihovny.cz E-zdroje
- Klíčová slova
- choroidal neovascularization, anti-VEGF, choroidal neovascular membrane in children, pediatric CNV, ranibizumab, secondary CNV,
- MeSH
- bevacizumab * aplikace a dávkování terapeutické užití MeSH
- dítě MeSH
- inhibitory angiogeneze * terapeutické užití aplikace a dávkování MeSH
- injekce intravitreální MeSH
- lidé MeSH
- mladiství MeSH
- neovaskularizace choroidey * farmakoterapie diagnóza etiologie MeSH
- optická koherentní tomografie MeSH
- předškolní dítě MeSH
- ranibizumab * terapeutické užití aplikace a dávkování MeSH
- retrospektivní studie MeSH
- vaskulární endoteliální růstový faktor A * antagonisté a inhibitory MeSH
- výsledek terapie MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- bevacizumab * MeSH
- inhibitory angiogeneze * MeSH
- ranibizumab * MeSH
- vaskulární endoteliální růstový faktor A * MeSH
AIM: To evaluate the epidemiological data, etiology and clinical characteristics, and to assess the efficacy and safety of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy in the treatment of choroidal neovascular membrane (CNV) in children and adolescents. The results are compared with data from previously published studies and case reports. MATERIAL AND METHODS: Retrospective analysis of medical records of patients treated for CNV at the Department of Pediatric Ophthalmology, University Hospital Brno, between January 2015 and April 2025. The cohort consisted of 12 patients, including 7 males and 5 females. All the cases involved unilateral disease; the right eye was affected in 7 patients and the left eye in 5. The mean age at onset was 11.8 years (range: 3-17 years). All underwent a comprehensive ophthalmological examination including optical coherence tomography (OCT); in 7 cases the diagnosis was confirmed by fluorescein angiography. The evaluated parameters included epidemiological data, clinical and morphological characteristics of CNV before and after anti-VEGF therapy. The etiology of CNV in our cohort was as follows: post-inflammatory/post-infectious in 6 cases, idiopathic in 3 cases, and one case each of myopic, post-traumatic, and neoplastic origin. The most common localization was subfoveal. All CNV lesions were classified as classic (type 2). RESULTS: All patients achieved either anatomical or functional improvement. No ocular or systemic adverse effects related to intravitreal anti-VEGF therapy were observed during the study period. CONCLUSION: Early diagnosis and intervention with anti-VEGF therapy show favorable outcomes, including stabilization and remission of the disease. In our cohort, no adverse events or complications associated with intravitreal anti-VEGF administration were recorded. Continued research is essential in order to gain a further understanding of the pathogenesis of pediatric CNV and to optimize treatment strategies in children.
Citace poskytuje Crossref.org